BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Adaptimmune Therapeutics Stock (ADAP) Surges Despite Weiss ’Sell’ Rating
Adaptimmune Therapeutics Stock (ADAP) Surges Despite Weiss ’Sell’ Rating
7
2
BTCCSquare news:
Adaptimmune Therapeutics PLC (ADAP) continues its volatile rally, climbing 11% in pre-market trading after a 52% surge the previous day. The biotech firm, focused on T-cell therapies for solid tumors, defies a stark "Sell (E+)" rating from Weiss Ratings—a designation signaling severe financial and operational risks.
Year-to-date losses exceed 60%, with the stock languishing 75% below its 52-week high of $0.91. Speculative momentum appears to override fundamental concerns, as investors chase the penny stock's erratic movements. Weiss' assessment underscores deeper vulnerabilities, contrasting sharply with the market's short-term appetite for high-risk plays.
By:
